“Moderna’s role in fighting the pandemic provided some significant benefits,” said Asher Rogovy, who is the Chief Investment Officer at Magnifina, LLC. “Operation Warp Speed provided Moderna with $1.53 billion to help its R&D and production capacity.”
“Novavax uses a tried-and-true method to produce immunity,” said Asher Rogovy, who is the Chief Investment Officer at Magnifina.
Investment advice offered through Magnifina, LLC, a Registered Investment Adviser. SEC# 801-117932. This website and information are provided for guidance and information purposes only and are not intended to provide investment, tax, or legal advice. No historical or future performance claims are made. Please consult a qualified professional before making decisions about your financial situation or otherwise using any specific information contained herein.
Any linked materials are provided strictly as a courtesy. We make no representation as to the completeness or accuracy of information provided at these websites. When you access one of these websites, you are leaving our website and assume total responsibility and risk for your use of the websites you are viewing.
Any service described as “free” or “complimentary” means there is no monetary or financial cost to you. However, these offers may require you to be in contact with us, provide certain information, or participate in meetings or consultations. We reserve the right to deny, discontinue, or limit access to any offer at our sole discretion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
25 Broadway, 10th Floor
New York, NY 10004
Phone: (800) 732-0818
